Category: ADC Therapeutics

Sobi bolsters blood division via $435m ADC licensing deal

July 8, 2022 Auto Bot 0

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last […]

EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout

June 13, 2022 Auto Bot 0

ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in […]

ADC Therapeutics strikes a $325M royalty deal to fuel its cancer drug strategy

August 26, 2021 Auto Bot 0

The royalty agreement with HealthCare Royalty Partners will support ADC Therapeutics’ plans to commercialize its newly approved cancer drug and develop the next one in […]

Insights+: The US FDA New Drug Approvals in April 2021

May 13, 2021 Auto Bot 0

The US FDA has approved 3 NDAs and 2 BLAs in April 2021, leading to treatments for patients and advances in the health care industry. […]

FDA approves ADC Therapeutics antibody drug conjugate in B-cell lymphoma

April 26, 2021 Auto Bot 0

With FDA approval of Zynlonta, ADC Therapeutics can offer patients who have diffuse large B-cell lymphoma an option if CAR-T therapy doesn’t work. Additional clinical […]

Antibody Drug Conjugates (ADCs): A Deeper Look into Contract Manufacturing Landscape

January 6, 2021 Auto Bot 0

Antibody Drug Conjugates (ADCs) known as the 21st Century Magic Bullets, have emerged as a promising class of targeted therapies being developed for the treatment […]